Go for IOP Control From the Start
BAUSCH + LOMB Access Program
Description: VYZULTATM (latanoprostene bunod ophthalmic solution), 0.024% is now approved. Read prescribing information and complete a quick form for more information.
By submitting your information you confirm you have read and agree with the terms of our Privacy Policy and Legal Notice .
*As of date of FDA approval of VYZULTA.
VYZULTA ® (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.
Go for IOP Control From the Start
BAUSCH + LOMB Access Program